Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Androgen receptor inhibitor
DRUG CLASS:
Androgen receptor inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
enzalutamide (78)
darolutamide (14)
bicalutamide (13)
flutamide (4)
EPI-7170 (1)
ONCT-534 (1)
SID 3712502 (1)
rezvilutamide (0)
MVI-118 (0)
enzalutamide tablet (0)
enzalutamide (78)
darolutamide (14)
bicalutamide (13)
flutamide (4)
EPI-7170 (1)
ONCT-534 (1)
SID 3712502 (1)
rezvilutamide (0)
MVI-118 (0)
enzalutamide tablet (0)
›
Associations
(114)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
enzalutamide
Sensitive: A1 - Approval
enzalutamide
Sensitive
:
A1
enzalutamide
Sensitive: A1 - Approval
enzalutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
darolutamide
Sensitive
:
A1
darolutamide
Sensitive: A1 - Approval
darolutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
goserelin acetate + flutamide
Sensitive: A1 - Approval
goserelin acetate + flutamide
Sensitive
:
A1
goserelin acetate + flutamide
Sensitive: A1 - Approval
goserelin acetate + flutamide
Sensitive
:
A1
HRD
Prostate Cancer
HRD
Prostate Cancer
talazoparib + enzalutamide
Sensitive: A1 - Approval
talazoparib + enzalutamide
Sensitive
:
A1
talazoparib + enzalutamide
Sensitive: A1 - Approval
talazoparib + enzalutamide
Sensitive
:
A1
AR splice variant 7
Prostate Cancer
AR splice variant 7
Prostate Cancer
enzalutamide
Resistant: A2 - Guideline
enzalutamide
Resistant
:
A2
enzalutamide
Resistant: A2 - Guideline
enzalutamide
Resistant
:
A2
AR positive
Salivary Gland Cancer
AR positive
Salivary Gland Cancer
bicalutamide
Sensitive: A2 - Guideline
bicalutamide
Sensitive
:
A2
bicalutamide
Sensitive: A2 - Guideline
bicalutamide
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
bicalutamide + goserelin acetate
Sensitive: A2 - Guideline
bicalutamide + goserelin acetate
Sensitive
:
A2
bicalutamide + goserelin acetate
Sensitive: A2 - Guideline
bicalutamide + goserelin acetate
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
bicalutamide + triptorelin
Sensitive: A2 - Guideline
bicalutamide + triptorelin
Sensitive
:
A2
bicalutamide + triptorelin
Sensitive: A2 - Guideline
bicalutamide + triptorelin
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
triptorelin + flutamide
Sensitive: A2 - Guideline
triptorelin + flutamide
Sensitive
:
A2
triptorelin + flutamide
Sensitive: A2 - Guideline
triptorelin + flutamide
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
leuprolide acetate + bicalutamide
Sensitive: A2 - Guideline
leuprolide acetate + bicalutamide
Sensitive
:
A2
leuprolide acetate + bicalutamide
Sensitive: A2 - Guideline
leuprolide acetate + bicalutamide
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
leuprolide acetate + flutamide
Sensitive: A2 - Guideline
leuprolide acetate + flutamide
Sensitive
:
A2
leuprolide acetate + flutamide
Sensitive: A2 - Guideline
leuprolide acetate + flutamide
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
bicalutamide + histrelin acetate
Sensitive: A2 - Guideline
bicalutamide + histrelin acetate
Sensitive
:
A2
bicalutamide + histrelin acetate
Sensitive: A2 - Guideline
bicalutamide + histrelin acetate
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
histrelin acetate + flutamide
Sensitive: A2 - Guideline
histrelin acetate + flutamide
Sensitive
:
A2
histrelin acetate + flutamide
Sensitive: A2 - Guideline
histrelin acetate + flutamide
Sensitive
:
A2
AR amplification
Prostate Cancer
AR amplification
Prostate Cancer
enzalutamide
Resistant: B - Late Trials
enzalutamide
Resistant
:
B
enzalutamide
Resistant: B - Late Trials
enzalutamide
Resistant
:
B
PTEN mutation
Prostate Cancer
PTEN mutation
Prostate Cancer
bicalutamide
Sensitive: B - Late Trials
bicalutamide
Sensitive
:
B
bicalutamide
Sensitive: B - Late Trials
bicalutamide
Sensitive
:
B
TP53 deletion
Prostate Cancer
TP53 deletion
Prostate Cancer
enzalutamide
Resistant: B - Late Trials
enzalutamide
Resistant
:
B
enzalutamide
Resistant: B - Late Trials
enzalutamide
Resistant
:
B
RB1 deletion
Prostate Cancer
RB1 deletion
Prostate Cancer
enzalutamide
Resistant: B - Late Trials
enzalutamide
Resistant
:
B
enzalutamide
Resistant: B - Late Trials
enzalutamide
Resistant
:
B
BRCA2 deletion
Prostate Cancer
BRCA2 deletion
Prostate Cancer
enzalutamide
Sensitive: B - Late Trials
enzalutamide
Sensitive
:
B
enzalutamide
Sensitive: B - Late Trials
enzalutamide
Sensitive
:
B
CD8 expression
Prostate Cancer
CD8 expression
Prostate Cancer
atezolizumab + enzalutamide
Sensitive: B - Late Trials
atezolizumab + enzalutamide
Sensitive
:
B
atezolizumab + enzalutamide
Sensitive: B - Late Trials
atezolizumab + enzalutamide
Sensitive
:
B
PD-L1 overexpression
Prostate Cancer
PD-L1 overexpression
Prostate Cancer
atezolizumab + enzalutamide
Sensitive: B - Late Trials
atezolizumab + enzalutamide
Sensitive
:
B
atezolizumab + enzalutamide
Sensitive: B - Late Trials
atezolizumab + enzalutamide
Sensitive
:
B
AR wild-type
Prostate Cancer
AR wild-type
Prostate Cancer
enzalutamide
Sensitive: B - Late Trials
enzalutamide
Sensitive
:
B
enzalutamide
Sensitive: B - Late Trials
enzalutamide
Sensitive
:
B
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
talazoparib + enzalutamide
Sensitive: B - Late Trials
talazoparib + enzalutamide
Sensitive
:
B
talazoparib + enzalutamide
Sensitive: B - Late Trials
talazoparib + enzalutamide
Sensitive
:
B
AR splice variant 7 negative
Prostate Cancer
AR splice variant 7 negative
Prostate Cancer
enzalutamide
Sensitive: B - Late Trials
enzalutamide
Sensitive
:
B
enzalutamide
Sensitive: B - Late Trials
enzalutamide
Sensitive
:
B
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
ONCT-534
Sensitive: B - Late Trials
ONCT-534
Sensitive
:
B
ONCT-534
Sensitive: B - Late Trials
ONCT-534
Sensitive
:
B
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
enzalutamide
Sensitive: C2 – Inclusion Criteria
enzalutamide
Sensitive
:
C2
enzalutamide
Sensitive: C2 – Inclusion Criteria
enzalutamide
Sensitive
:
C2
AR positive
Triple Negative Breast Cancer
AR positive
Triple Negative Breast Cancer
enzalutamide
Sensitive: C2 – Inclusion Criteria
enzalutamide
Sensitive
:
C2
enzalutamide
Sensitive: C2 – Inclusion Criteria
enzalutamide
Sensitive
:
C2
AR positive
Triple Negative Breast Cancer
AR positive
Triple Negative Breast Cancer
darolutamide
Sensitive: C2 – Inclusion Criteria
darolutamide
Sensitive
:
C2
darolutamide
Sensitive: C2 – Inclusion Criteria
darolutamide
Sensitive
:
C2
AR positive
Salivary Gland Cancer
AR positive
Salivary Gland Cancer
darolutamide
Sensitive: C2 – Inclusion Criteria
darolutamide
Sensitive
:
C2
darolutamide
Sensitive: C2 – Inclusion Criteria
darolutamide
Sensitive
:
C2
AR F877L
Prostate Cancer
AR F877L
Prostate Cancer
enzalutamide
Resistant: C3 – Early Trials
enzalutamide
Resistant
:
C3
enzalutamide
Resistant: C3 – Early Trials
enzalutamide
Resistant
:
C3
AR positive
Salivary Gland Cancer
AR positive
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + bicalutamide
Sensitive
:
C3
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + bicalutamide
Sensitive
:
C3
PLIN2 expression
Salivary Gland Cancer
PLIN2 expression
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + bicalutamide
Sensitive
:
C3
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + bicalutamide
Sensitive
:
C3
AR F876L
Prostate Cancer
AR F876L
Prostate Cancer
enzalutamide
Resistant: C3 – Early Trials
enzalutamide
Resistant
:
C3
enzalutamide
Resistant: C3 – Early Trials
enzalutamide
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login